MX2023000679A - Inhibidores del factor c3 del complemento y sus usos medicos. - Google Patents
Inhibidores del factor c3 del complemento y sus usos medicos.Info
- Publication number
- MX2023000679A MX2023000679A MX2023000679A MX2023000679A MX2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A
- Authority
- MX
- Mexico
- Prior art keywords
- compstatin
- analogues
- complement
- introduction
- inhibiting activity
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 abstract 2
- 108010027437 compstatin Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
Se describen análogos de compstatina que tienen propiedades fisicoquímicas mejoradas, tales como estabilidad y/o solubilidad aumentadas en comparación con el péptido de compstatina de 13 aminoácidos, en particular análogos de compstatina que además poseen actividad de unión e inhibición del complemento útil. Estos análogos tienen un puente alquileno entre los átomos de azufre de los restos de cisteína e incluyen variantes con un resto de isoleucina en la posición 3 en lugar del resto de valina de tipo silvestre, lo que proporciona a los péptidos de compstatina una mejor unión y actividad inhibidora del complemento y también permite la introducción de otras modificaciones, por ejemplo, modificaciones que son capaces de aumentar la estabilidad, tal como la introducción de lisina o serina en la posición 11.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20186297 | 2020-07-16 | ||
| PCT/EP2021/069798 WO2022013374A1 (en) | 2020-07-16 | 2021-07-15 | Inhibitors of complement factor c3 and their medical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000679A true MX2023000679A (es) | 2023-04-18 |
Family
ID=71661768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000679A MX2023000679A (es) | 2020-07-16 | 2021-07-15 | Inhibidores del factor c3 del complemento y sus usos medicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230287051A1 (es) |
| EP (1) | EP4182023A1 (es) |
| JP (1) | JP2023538807A (es) |
| KR (1) | KR20230039718A (es) |
| CN (1) | CN116209671A (es) |
| AU (1) | AU2021309548A1 (es) |
| CA (1) | CA3185730A1 (es) |
| CO (1) | CO2023001411A2 (es) |
| IL (1) | IL299870A (es) |
| MX (1) | MX2023000679A (es) |
| WO (1) | WO2022013374A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319897B1 (en) | 1996-03-13 | 2001-11-20 | John D. Lambris | Peptides which inhibit complement activation |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1999013899A1 (en) | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| SI1549333T1 (sl) | 2002-09-20 | 2012-02-29 | Univ Pennsylvania | Analogi kompstatina z izboljĺ ano aktivnostjo |
| BRPI0617186A2 (pt) | 2005-10-08 | 2011-07-19 | Potentia Pharmaceuticals Inc | uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste |
| PT1960422E (pt) | 2005-11-28 | 2012-08-16 | Univ Pennsylvania | Análogos de compstatina potentes |
| US8442776B2 (en) | 2007-06-08 | 2013-05-14 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-C3 complex and use for rational drug design |
| CA2813049A1 (en) * | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| JP6249949B2 (ja) | 2011-09-07 | 2017-12-20 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 薬物動態特性の改善されたコンプスタチンアナログ |
| WO2014100407A1 (en) | 2012-12-19 | 2014-06-26 | The Regents Of The University Of California | Compstatin analogs |
| KR20200135797A (ko) * | 2018-02-27 | 2020-12-03 | 제트피 에스피브이 3 케이/에스 | 콤프스타틴 유사체 및 이들의 의학적 용도 |
-
2021
- 2021-07-15 CN CN202180062742.5A patent/CN116209671A/zh active Pending
- 2021-07-15 IL IL299870A patent/IL299870A/en unknown
- 2021-07-15 KR KR1020237005557A patent/KR20230039718A/ko unknown
- 2021-07-15 JP JP2023502703A patent/JP2023538807A/ja active Pending
- 2021-07-15 EP EP21742144.5A patent/EP4182023A1/en active Pending
- 2021-07-15 AU AU2021309548A patent/AU2021309548A1/en active Pending
- 2021-07-15 US US18/016,490 patent/US20230287051A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069798 patent/WO2022013374A1/en unknown
- 2021-07-15 MX MX2023000679A patent/MX2023000679A/es unknown
- 2021-07-15 CA CA3185730A patent/CA3185730A1/en active Pending
-
2023
- 2023-02-09 CO CONC2023/0001411A patent/CO2023001411A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4182023A1 (en) | 2023-05-24 |
| WO2022013374A1 (en) | 2022-01-20 |
| KR20230039718A (ko) | 2023-03-21 |
| CA3185730A1 (en) | 2022-01-20 |
| AU2021309548A1 (en) | 2023-02-23 |
| JP2023538807A (ja) | 2023-09-12 |
| IL299870A (en) | 2023-03-01 |
| CN116209671A (zh) | 2023-06-02 |
| US20230287051A1 (en) | 2023-09-14 |
| CO2023001411A2 (es) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011325910B2 (en) | Cancer therapies and diagnostics | |
| EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
| EA200901459A1 (ru) | Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства | |
| MX2020008902A (es) | Analogos de compstatina y sus usos medicos. | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| KR20090115852A (ko) | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 | |
| MX2009007008A (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo. | |
| EP4272751A3 (en) | Compstatin analogues and their medical uses | |
| MX2023000679A (es) | Inhibidores del factor c3 del complemento y sus usos medicos. | |
| EP1502949A4 (en) | ANTIMICROBIAL POLYPEPTIDE AND USE THEREOF | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| Chionis et al. | Synthesis and biological activity of lipophilic analogs of the cationic antimicrobial active peptide anoplin | |
| SE0301431D0 (sv) | Novel antimicrobial peptides | |
| MX2020010520A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas. | |
| CY1112839T1 (el) | Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ | |
| EP2089419A2 (en) | Inhibition of beta-amyloid aggregation | |
| Debowski et al. | Hybrid analogues of SFTI‐1 modified in P1 position by β‐and γ‐amino acids and N‐substituted β‐alanines | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| AU2008237138B2 (en) | Methods of use of gamma inhibitor compounds for the attenuation of pain | |
| EA202192793A1 (ru) | Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью | |
| SE9700301D0 (sv) | New compound | |
| FR3071504B1 (fr) | Produit biologique pour ameliorer la stabilite proteique de boissons a base de mouts vegetaux | |
| Hilchie et al. | Obstacles and solutions to the use of cationic antimicrobial peptides in the treatment of cancer | |
| TH127104B (th) | สารลดความตึงผิวที่ถูกประกอบขึ้นใหม่โดยมีคุณสมบัติที่ได้รับการปรับปรุงให้ดีขึ้น |